Metabolomics Market worth $1.5 Billion – 2017

The report “Metabolomics (Biomarker Discovery/Metabolite Detection/Metabolite Profiling) Market By Applications (Drug Discovery/Toxicology Assessment/ Diagnosis) and Indications (Oncology/Cardiology/Neurology) – Forecasts from 2012 to 2017″ analyses the global metabolomics market by region, applications and indications with five year revenue forecasts. It also identifies the factors driving and restraining the global metabolomics market with analysis of trends, opportunities and challenges.


  • 17 market data tables
  • 36 figures
  • 136 slides and an in-depth Table of Content on ” Metabolomics Market “

Request Sample

The market is segmented and the revenue is forecasted on the basis of major regions such as America, Europe, Asia and Rest of the World (ROW) covering the key countries for each region. Further, the market is also segmented and revenues are forecasted on the basis of applications and disease indications.

In the post genomic era, metabolomics is gaining importance as another promising “omic” technology for understanding the biology of various diseases. Rapid advancement has been occurring in prediction, detection, monitoring and understanding of various diseases using metabolomic technologies.

The market for metabolomic data analysis tools and software is increasing at a higher rate. Metabolomics allows pharma companies to stretch their R&D efforts by improving efficiency in target discovery and validation, mode-of-action, and toxicology studies. There has been a significant global growth in biotechnology and pharmaceutical industries in the last decade and the market is expected to have a double-digit growth rate in the coming years.

Biomarker discovery services and increased need for toxicity testing are driving the metabolomics market. Nutraceuticals, plant genomics, nutri-genomics, systems biology are some high growth and emerging application areas that are expected to drive the global market of metabolomics in coming years. The global market for metabolomics in terms of revenue is estimated to be worth $343 million in 2012 and is expected to reach $1.5 billion by 2017, growing at a CAGR of 35% from 2012 to 2017.

About MarketsandMarkets

MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.

Mr. Rohan
North – Dominion Plaza,
17304 Preston Road,
Suite 800, Dallas, TX 75252
Tel: +1-888-6006-441

Share this post:

Recent Posts

Comments are closed.